Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation

被引：0
|
作者：
Andronikou, Christina
Burdova, Kamila
Dibitetto, Diego
Lieftink, Cor
Beijersbergen, Roderick L.
Hanzlikova, Hana
Jonkers, Jos
Rottenberg, Sven
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-LB_A25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB_A25
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors
    Bauer, S.
    Demetri, G.
    Jeay, S.
    Dummer, R.
    Guerreiro, N.
    Tan, D. S.
    Kumar, A.
    Meille, C.
    Van Bree, L.
    Halilovic, E.
    Wuerthner, J. U.
    Cassier, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [42] Preliminary results from HERKULES-1: a phase 1b/2, open-label, multi-center study of ERAS-007, an oral ERK1/2 inhibitor, in patients with advanced or metastatic solid tumors
    Wang, J.
    Johnson, M.
    Barve, M.
    Pelster, M.
    Chen, X.
    Li, Z.
    Gordon, J.
    Reiss, M.
    Pai, S.
    Falchook, G.
    Tolcher, A.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S80 - S81
  • [43] Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.
    Niu, Jiaxin
    Kaufman, Howard L.
    Kichenadasse, Ganessan
    Haydon, Andrew Mark
    Barve, Minal A.
    Ganju, Vinod
    Buchbinder, Elizabeth Iannotti
    Spira, Alexander I.
    Pang, Weijia
    Fu, Wenmin
    Zhao, Min
    Kirkwood, John M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Phase 1 trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study
    Lulla, Rishi R.
    Goldman, Stewart
    Yamada, Tohru
    Beattie, Craig W.
    Bressler, Linda
    Pacini, Michael
    Pollack, Ian F.
    Fisher, Paul Graham
    Packer, Roger J.
    Dunkel, Ira J.
    Dhall, Girish
    Wu, Shengjie
    Onar, Arzu
    Boyett, James M.
    Fouladi, Maryam
    NEURO-ONCOLOGY, 2016, 18 (09) : 1319 - 1325
  • [45] Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
    McKean, M.
    Barve, M.
    Hong, D.
    Parikh, A.
    Rosen, E.
    Yang, J.
    Picard, R.
    Yi, J.
    Brail, L.
    Vecchio, D.
    Meniawy, T.
    John, T.
    Wang, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S34 - S34
  • [46] Preliminary results from the Phase I part of a first-in-human Phase I/II study of HH2853, an EZH1/2 inhibitor, in patients with relapsed/refractory non-Hodgkin lymphomas or advanced solid tumors
    Fan, Zhengfu
    Wang, Jin
    Fang, Meiyu
    Patrick, Johnston
    Han, Tun
    Sommerhalder, David
    Gong, Jifang
    Yang, Jilong
    Yang, Yun
    Munoz, Javier
    Song, Yuqin
    Li, Zhiming
    Li, Xian'an
    Ma, Qiuying
    Han, Jinming
    Shen, Lin
    Zhu, Jun
    CANCER RESEARCH, 2023, 83 (08)
  • [47] A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation
    Lee, Jeeyun
    Cho, Byoung Chul
    Lee, Jae-Lyun
    Lee, Jung-Yun
    Ma, Wen Wee
    Adjei, Alex A.
    Campian, Jian Li
    Zhao, Yujie
    Seetharam, Mahesh
    Shim, Byoung Yong
    Yun, Nari
    Lee, Woohyung Wayne
    Park, Sujeong
    Lee, Woosun
    Park, Sosun
    Kim, Jay
    Seo, Bochan
    Kim, Ryunhee
    Jang, Myoung Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors
    Tolcher, Anthony
    Hafez, Navid
    Yamamoto, Noboru
    Park, Jaehong
    Grempler, Rolf
    Lucarelli, Anthony
    Vallaster, Markus P.
    Wang, Bushi
    Hyman, David
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [49] Results from CA240-0007, a phase 1/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)
    Rodon, J.
    Janne, P. A.
    Leventakos, K.
    George, B.
    Henry, J. T.
    Johnson, M. L.
    Papadopoulos, K. P.
    Batista, A. I.
    Spira, C. P.
    Zhao, Y.
    Zuniga, R.
    Shoukier, M.
    Ernani, V.
    Haddox, C. L.
    Wozniak, A.
    Mariotti, V.
    Mazzei-Abba, A.
    Shazer, R.
    Yang, W.
    Arbour, K. C.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S178 - S180
  • [50] SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001)
    Hollebecque, Antoine
    Lopez, Juanita Suzanne
    Piha-Paul, Sarina A.
    Dowlati, Afshin
    Patnaik, Amita
    Galvao, Vladimir
    Bockorny, Bruno
    Sehgal, Kartik
    Kingsley, Ed
    Sanborn, Rachel E.
    Perez, Cesar Augusto
    Peters, Solange
    Yan, Mingjin
    Nazarenko, Natalya N.
    Calvo, Emiliano
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345